

# Pediatric Oncology I Panel

---

## Series Editors:

### **Marcia L. Buck, Pharm.D., BCPPS, FCCP, FPPAG**

*Clinical Coordinator*  
University of Virginia Children's Hospital  
*Professor*  
Department of Pediatrics  
University of Virginia School of Medicine  
*Clinical Professor*  
Virginia Commonwealth University School of Pharmacy  
Department of Pharmacy Services  
University of Virginia Health System  
Charlottesville, Virginia

### **Kalen B. Manasco, Pharm.D., FCCP, BCPS**

*Clinical Professor*  
University of Florida College of Pharmacy  
Gainesville, Florida

## Faculty Panel Chair:

### **Betsy M. Bickert Poon, Pharm.D., FCCP**

*Assistant Director of Pharmacy*  
Disney Pavilion at Florida Hospital for Children  
Brandon, Florida

## PEDIATRIC CANCER TREATMENT DEVELOPMENT

### Authors

#### **Cynthia Jiles, R.Ph., BSPHarm**

*Senior Clinical Research Pharmacist*  
Pharmaceutical Management Branch  
Cancer Therapy Evaluation Program  
Division of Cancer Treatment and Diagnosis  
National Cancer Institute  
Rockville, Maryland

#### **Eileen Wu, Pharm.D.**

*Senior Clinical Research Pharmacist*  
Pharmaceutical Management Branch  
Cancer Therapy Evaluation Program  
Division of Cancer Treatment and Development  
National Cancer Institute  
Rockville, Maryland

### Reviewers

#### **M. Brooke Bernhardt, Pharm.D., M.S., BCOP, BCPPS**

*Assistant Director of Clinical Services and Outcomes*  
Pharmacy Department  
Texas Children's Hospital  
Houston, Texas

#### **Salem Kamalay, Pharm.D., BCPS, BCPPS**

*Clinical Pharmacist*  
Department of Pharmaceutical Services  
University of California, San Francisco Medical Center  
San Francisco, California

## ASPARAGINASE MONITORING IN PATIENTS WITH LEUKEMIA

### Author

#### **Tamara MacDonald, Pharm.D.**

*Clinical Pharmacy Specialist*  
Hematology/Oncology  
Faculties of Medicine and Health Professions,  
Dalhousie University/IWK Health Centre  
Halifax, Nova Scotia

### Reviewers

#### **Kerry Parsons, Pharm.D., FHOPA, BCOP**

*Oncology Medical Science Liaison*  
AstraZeneca Pharmaceuticals  
Helena, Alabama

#### **Manal M. Abouelkheir, Pharm.D., BCPS, BCPPS**

*Pediatric Clinical Pharmacist*  
Department of Pharmacy Services  
King Saud University Medical City  
*Adjunct Assistant Professor*  
Department of Clinical Pharmacy  
College of Pharmacy-King Saud University  
Riyadh, Saudi Arabia

#### **Melissa Ray, Pharm.D., BCPS, BCPPS**

*Clinical Pharmacist III*  
United Health Group  
Tampa, Florida  
*Clinical Assistant Professor of Pharmacy Practice*  
University of Florida College of Pharmacy  
Gainesville, Florida

## BIOSIMILAR USE IN PEDIATRIC ONCOLOGY

### Author

#### **Rachel Langlely, Pharm.D., BCPPS**

*Hematology/Oncology Clinical Pharmacist*  
St. Louis Children's Hospital  
St. Louis, Missouri

## Reviewers

### **Olga Militano, Pharm.D.**

*Pharmacist*  
Study Development Office  
Children's Oncology Group  
Monrovia, California

### **Allison L. Salinas, Pharm.D., BCPPS**

*Clinical Pharmacist*  
Children's Hospital Colorado  
Aurora, Colorado

### **Tara Leigh Smith, Pharm.D., M.S., BCPPS**

*Clinical Pharmacy Manager*  
Sacred Heart hospital  
Gulf Breeze, Florida

### **Emilie L. Karpiuk, Pharm.D., BCPS**

*Oncology Pharmacist*  
Department of Pharmacy  
Froedtert Hospital  
Milwaukee, Wisconsin

### **Lynn Kassel, Pharm.D., BCPS**

*Assistant Professor*  
Department of Clinical Sciences  
Drake University College of Pharmacy & Health Sciences  
Des Moines, Iowa  
*Acute Care Pharmacist*  
Mercy West Lakes Hospital  
Clive, Iowa

The American College of Clinical Pharmacy and the authors thank the following individuals for their careful review of the Pediatric Oncology I:

## DISCLOSURE OF POTENTIAL CONFLICTS OF INTEREST

**Consultancies:** Nicole Arwood (Navigant Consulting, Inc.); Rachel Langley (Syntaxx Communications); Melissa Ray (Therapeutics Research Center);

**Stock Ownership:** Jeanne M. Brady (Charles Schwab)

**Royalties:**

**Grants:** Tamara MacDonald (Jazz Pharmaceuticals); Yee Chang Soh (Ministry of Education, Malaysia, Universiti Teknologi); Devona Williams (Jazz Pharmaceuticals)

**Honoraria:** Tamara MacDonald (Syntaxx Communications); Yee Chang Soh (UCSI University Kuala Lumpur, Malaysia); Devona Williams (Jazz Pharmaceuticals)

**Other:** Kerry Parsons (employed by AstraZeneca Pharmaceuticals)

**Nothing to disclose:** M. Brooke Bernhardt; Elizabeth A. Boucher; Shane Cross; Rebecca Deoras; Manal M. Abou Elkheir; Karen Gradischer; Amy Helvie; Cynthia Jiles; Salem Kamalay; Olga Militano; Margaret Oates Poisson; Andrew Ostrenga; Jennifer L. Pauley; Allison L. Salinas; Caroline M. Sierra; Tara Leigh Smith; Brenda Winger; Eileen Wu

**ROLE OF BPS:** The Board of Pharmacy Specialties (BPS) is an autonomous division of the American Pharmacists Association (APhA). BPS is totally separate and distinct from ACCP. The Board, through its specialty councils, is responsible for specialty examination content, administration, scoring, and all other aspects of its certification programs. PedSAP has been approved by BPS for use in BCPPS recertification. Information about the BPS recertification process is available [online](#).

**Questions regarding BCPPS recertification should be directed to:**

[Board of Pharmacy Specialties](#)

2215 Constitution Avenue NW

Washington, DC 20037

(202) 429-7591